Literature DB >> 3498438

In vitro susceptibility of 96 Capnocytophaga strains, including a beta-lactamase producer, to new beta-lactam antibiotics and six quinolones.

G Arlet, M J Sanson-Le Pors, I M Casin, M Ortenberg, Y Perol.   

Abstract

The in vitro activities of new beta-lactam antibiotics and new quinolones were studied against 96 Capnocytophaga strains, including a beta-lactamase-producing strain which was resistant to ampicillin, amoxicillin, carbenicillin, cephalothin, and cefamandole. All strains were susceptible to the combination of amoxicillin and clavulanic acid, ureidopenicillins, cefoxitin, broad-spectrum cephalosporins, and imipenem. Cephalothin and cefamandole did not show good activity against most strains. All Capnocytophaga spp. were uniformly susceptible to the five new quinolones tested.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3498438      PMCID: PMC174921          DOI: 10.1128/AAC.31.8.1283

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  In vitro susceptibility of Capnocytophaga species to 29 antimicrobial agents.

Authors:  J L Rummens; B Gordts; H W Van Landuyt
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

2.  In vitro susceptibility of Capnocytophaga species to antimicrobial agents.

Authors:  P M Hawkey; S D Smith; J Haynes; H Malnick; S W Forlenza
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

3.  Capnocytophaga species: infections in nonimmunocompromised and immunocompromised hosts.

Authors:  D M Parenti; D R Snydman
Journal:  J Infect Dis       Date:  1985-01       Impact factor: 5.226

4.  Capnocytophaga sepsis: a newly recognised clinical entity in granulocytopenic patients.

Authors:  S W Forlenza; M G Newman; A I Lipsey; S E Siegel; U Blachman
Journal:  Lancet       Date:  1980-03-15       Impact factor: 79.321

5.  In vitro susceptibility of Capnocytophaga strains to 18 antimicrobial agents.

Authors:  V L Sutter; D Pyeatt; Y Y Kwok
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

6.  Rapid identification of Capnocytophaga isolated from septicemic patients.

Authors:  J E Kristiansen; A Bremmelgaard; H E Busk; O Heltberg; W Frederiksen; T Justesen
Journal:  Eur J Clin Microbiol       Date:  1984-06       Impact factor: 3.267

7.  Antimicrobial susceptibility of Capnocytophaga.

Authors:  S W Forlenza; M G Newman; A L Horikoshi; U Blachman
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

8.  API ZYM system for identification of Bacteroides spp., Capnocytophaga spp., and spirochetes of oral origin.

Authors:  B E Laughon; S A Syed; W J Loesche
Journal:  J Clin Microbiol       Date:  1982-01       Impact factor: 5.948

9.  Capnocytophaga: new genus of gram-negative gliding bacteria. III. Physiological characterization.

Authors:  S S Socransky; S C Holt; E R Leadbetter; A C Tanner; E Savitt; B F Hammond
Journal:  Arch Microbiol       Date:  1979-07       Impact factor: 2.552

10.  Agar medium for use in susceptibility testing of bacteria from human periodontal pockets.

Authors:  C B Walker; T A Niebloom; S S Socransky
Journal:  Antimicrob Agents Chemother       Date:  1979-10       Impact factor: 5.191

View more
  14 in total

1.  Capnocytophaga ochracea: characterization of a plasmid-encoded extended-spectrum TEM-17 beta-lactamase in the phylum Flavobacter-bacteroides.

Authors:  A Rosenau; B Cattier; N Gousset; P Harriau; A Philippon; R Quentin
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

2.  Genetic analysis of an ambler class A extended-spectrum beta-lactamase from Capnocytophaga ochracea.

Authors:  Anne Jolivet-Gougeon; Zohreh Tamanai-Shacoori; Laurent Desbordes; Nathalie Burggraeve; Michel Cormier; Martine Bonnaure-Mallet
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

3.  Antimicrobial susceptibilities and beta-lactamase characterization of Capnocytophaga species.

Authors:  D L Roscoe; S J Zemcov; D Thornber; R Wise; A M Clarke
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

4.  Novel beta-lactamase from Capnocytophaga sp.

Authors:  J E Foweraker; P M Hawkey; J Heritage; H W Van Landuyt
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

Review 5.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

6.  Chromosome- and plasmid-encoded beta-lactamases in Capnocytophaga spp.

Authors:  Trude Handal; Chantal Giraud-Morin; Dominique A Caugant; Isabelle Madinier; Ingar Olsen; Thierry Fosse
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

7.  Brain abscess associated with multidrug-resistant Capnocytophaga ochracea infection.

Authors:  Hua-Kung Wang; Yee-Chun Chen; Lee-Jene Teng; Chien-Ching Hung; Mei-Lin Chen; Shin-Hei Du; Hui-Ju Pan; Po-Ren Hsueh; Shan-Chwen Chang
Journal:  J Clin Microbiol       Date:  2006-11-29       Impact factor: 5.948

Review 8.  Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Gonzalez; J M Henwood
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

9.  Bacteremia by multidrug-resistant Capnocytophaga sputigena.

Authors:  J L Gomez-Garces; J I Alos; J Sanchez; R Cogollos
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

10.  Capnocytophaga infection involving a portal-systemic vascular shunt.

Authors:  K A Mello; D R Snydman; S Arora
Journal:  Dig Dis Sci       Date:  1990-07       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.